Pharmaceutical

IGC Pharma heads towards a Phase I study for Alzheimer’s disease

With TGR-63 advancing towards the clinical stage, IGC Pharma is tackling different small molecule alternatives to treat Alzheimer’s.

Feb 2, 2024 - 18:00
IGC Pharma heads towards a Phase I study for Alzheimer’s disease
With TGR-63 advancing towards the clinical stage, IGC Pharma is tackling different small molecule alternatives to treat Alzheimer’s.
Read the original article

Tags:

Previous Article

BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales

Next Article

AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Colon cancer screening kits have a high rate of untestable samples

Colon cancer screening kits have a high rate of untesta...

Nov 17, 2023

STAT+: U.K. trade group suspends Novo Nordisk for ‘serious breaches’ in promoting obesity drug

STAT+: U.K. trade group suspends Novo Nordisk for ‘seri...

Mar 19, 2023

STAT+: Biden to tap head of National Cancer Institute to lead NIH

STAT+: Biden to tap head of National Cancer Institute t...

Apr 23, 2023